Beating the Big C
Pharmaceutical Technology
JULY 23, 2008
It has boosted anti-tumour research by 60% since 2005, at a cost of $1.6bn, in the hope of increasing the share of company sales attributed to cancer drugs from the current level of 5% “There are a lot of patients that are suffering,” said Pfizer chief executive Jeffrey Kindler. So what’s driving the growth?
52 
Let's personalize your content